Merck (MRK) Tops Q4 EPS by 4c, Offers FY Guidance

Merck (NYSE: MRK) reported Q4 EPS of $0.98, $0.04 better than the analyst estimate of $0.94. Revenue for the quarter came in at $10.4 billion versus the consensus estimate of $10.49 billion.

GUIDANCE:

Merck sees FY2018 EPS of $4.08-$4.23, versus the consensus of $4.11 on revenue of $41.2 to $42.7 billion vs $41.07 expected.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M